Galena Biopharma, Inc. (GALE) - NASDAQ
  • Jan. 13, 2014, 10:21 AM
    • Galena Biopharma (GALE +13.7%) rallies on news the company is buying Mills Pharmaceuticals, giving GALE rights to GALE-401 (CR anagrelide), a treatment for Essential Thrombocythemia.
    • In GALE's estimation, the drug "meets the qualifications for orphan drug status [and] has an estimated peak market size of approximately $200M in the U.S."
    • The company says a Phase 2 study should begin in "mid-2014."
    • GALE made an upfront payment to Mills' owners who are also eligible for stock grants and a milestone payment, the latter is contingent upon FDA approval of an NDA for '401. (PR)
    | Jan. 13, 2014, 10:21 AM | 5 Comments
Company Description
Galena Biopharma, Inc. is a biotechnology company focused on discovering, developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Its development portfolio ranges from mid to late stage clinical assets which include... More
Sector: Healthcare
Industry: Biotechnology
Country: United States